Artiva Biotherapeutics, Inc. (ARTV) Key Metrics
ARTV valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $286.0M
- Enterprise value
- $37.4M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 8.1
- Price / book
- 1.1
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- 2.41
ARTV key metrics, 2020–2025
Fiscal year ended December 31, 2025 · U.S. dollarsARTV valuation Price multiples at each fiscal year-end price.
ARTV returns How much profit the business earns on the capital it uses.
ARTV per-share figures Results divided by the shares outstanding at year-end.
ARTV financial health Debt, liquidity and how easily interest is covered.
ARTV valuation history
ARTV returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ARTV debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ARTV cash returned to shareholders
ARTV price vs earnings per share
ARTV key metrics
2020–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| Market capitalization | $104.9M | $245.6M | — | — | — | — |
| Enterprise value | $7.8M | $74.5M | — | — | — | — |
| Price / sales | — | 978.4 | — | — | — | — |
| Price / book | 1.0 | 1.3 | — | — | — | — |
| EV / sales | — | 296.8 | — | — | — | — |
| Earnings yield | −80.0% | −23.8% | — | — | — | — |
| Free cash flow yield | −75.7% | −22.7% | — | — | — | — |
| Shareholder yield (dividends + buybacks) | 0.0% | 1.7% | — | — | — | — |
| Share price at fiscal year-end | $4.29 | $10.08 | — | — | — | — |
| Per share | ||||||
| Revenue per share | $0.00 | $0.01 | $1.44 | $0.28 | $0.11 | $0.00 |
| Earnings per share | −$3.43 | −$2.40 | −$1.19 | −$3.32 | −$4.08 | −$1.02 |
| Operating cash flow per share | −$3.14 | −$2.26 | −$2.04 | −$2.89 | −$0.87 | −$0.77 |
| Free cash flow per share | −$3.25 | −$2.29 | −$2.18 | −$3.25 | −$0.97 | −$0.79 |
| Cash per share | $4.42 | $7.61 | $3.31 | $5.83 | $9.15 | $1.45 |
| Book value per share | $4.50 | $7.66 | −$6.96 | −$8.00 | −$5.05 | −$1.23 |
| Tangible book value per share | $4.50 | $7.66 | −$6.96 | −$8.00 | −$5.05 | −$1.23 |
| Capex per share | $0.11 | $0.03 | $0.14 | $0.36 | $0.10 | $0.02 |
| Debt per share | $0.45 | $0.59 | $0.73 | $1.11 | $0.10 | $0.12 |
| Shares outstanding | 24.4M | 24.4M | 23.3M | 17.6M | 17.6M | 17.6M |
| Change in shares outstanding | +0.3% | +4.6% | +32.4% | 0.0% | 0.0% | — |
| Returns & profitability | ||||||
| Return on equity (ROE) | −56.5% | −475.1% | — | — | — | — |
| Return on invested capital (ROIC) | −502.8% | — | — | — | — | — |
| Return on assets (ROA) | −49.3% | −37.2% | −23.3% | −38.5% | −72.1% | −61.5% |
| Return on tangible assets | −64.0% | −27.9% | −26.3% | −43.9% | −42.3% | −61.5% |
| Free cash flow margin | — | — | −151.3% | — | −850.5% | — |
| Financial health | ||||||
| Total debt | $10.9M | $14.4M | $16.9M | $19.4M | $1.7M | $2.1M |
| Cash & short-term investments | $108.0M | $185.4M | $77.0M | $102.5M | $160.9M | $25.4M |
| Net debt | −$97.1M | −$171.1M | −$60.1M | −$83.1M | −$159.2M | −$23.3M |
| Debt / equity | 0.10 | 0.08 | — | — | — | — |
| Debt / assets | 0.08 | 0.07 | 0.16 | 0.15 | 0.01 | 0.07 |
| Current ratio | 8.61 | 15.39 | 6.53 | 4.08 | 8.41 | 4.53 |
| Quick ratio | 8.61 | 15.39 | 6.53 | 4.08 | 8.41 | 4.53 |
| Interest coverage | — | — | — | — | — | -91.8 |
| Working capital | $99.6M | $176.4M | $67.6M | $79.0M | $143.0M | $20.3M |
| Invested capital | $12.9M | $15.6M | −$222.1M | −$223.8M | −$248.0M | −$44.9M |
| Tangible asset value | $110.0M | $186.6M | −$162.0M | −$140.7M | −$88.9M | −$21.6M |
| Net current asset value | $91.7M | $165.7M | −$187.3M | −$169.1M | −$96.5M | −$24.7M |
| Graham net-net per share | $3.58 | $6.67 | −$8.11 | −$9.72 | −$5.55 | −$1.44 |
| Capital allocation | ||||||
| Share buybacks (net) | $0 | $4.2M | $12,000 | $5,000 | — | — |
| Capex / revenue | — | 255.8% | 9.7% | 127.7% | 86.1% | — |
| Capex / depreciation | 1.00 | 0.26 | 1.44 | 5.44 | 6.95 | 3.89 |
| Stock-based compensation / revenue | — | 2,780.9% | 21.1% | 133.5% | 215.1% | — |
| R&D / revenue | — | 20,051.0% | 150.0% | 892.0% | 2,118.4% | — |
| SG&A / revenue | — | 6,854.6% | 41.5% | 421.3% | 642.6% | — |
| Efficiency | ||||||
| Days sales outstanding | — | 1,384.4 | 12.4 | 36.8 | 42.7 | — |
| Days payables outstanding | 103.7 | — | — | — | — | — |
| Receivables turnover | 0.00 | 0.26 | 29.34 | 9.93 | 8.56 | — |
| Payables turnover | 3.52 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Asset turnover | 0.00 | 0.00 | 0.28 | 0.03 | 0.02 | 0.00 |
| Average receivables | $456,500 | $952,000 | $1.1M | $496,500 | $234,000 | $0 |
| Average payables | $738,000 | $867,500 | $855,000 | $1.3M | $1.8M | $2.2M |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from ARTV's annual financial statements (latest annual report filed March 10, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ARTV valuation and financial ratios
Artiva Biotherapeutics earned a return on equity of −56.5% and a return on invested capital of −502.8% in fiscal 2025. It ended the year with $10.9 million of debt and $108.0 million in cash and short-term investments, a net cash position of $97.1 million. The share count rose 39.0% from 17.6M to 24.4M over 5 years.
See the ARTV income statement, the ARTV chart for price history, or the ARTV stock overview for the latest quote and news.
ARTV key metrics FAQ
What is Artiva Biotherapeutics's return on equity?
Artiva Biotherapeutics's return on equity (ROE) was −56.5% in fiscal 2025: net income of -$83.9 million on average shareholders' equity of $148.3 million.
What is Artiva Biotherapeutics's ROIC?
Artiva Biotherapeutics's return on invested capital was −502.8% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Artiva Biotherapeutics have?
Artiva Biotherapeutics had total debt of $10.9 million at the end of fiscal 2025, a debt-to-equity ratio of 0.10 and more cash than debt.
What is Artiva Biotherapeutics's free cash flow yield?
Artiva Biotherapeutics generated -$79.3 million of free cash flow in fiscal 2025, a free cash flow yield of −75.7% on its market value at year-end ($104.9 million).
What is Artiva Biotherapeutics's current ratio?
Artiva Biotherapeutics's current ratio was 8.61 at the end of fiscal 2025: current assets were 8.61 times current liabilities.